ICC panel rules in cancer treatment dispute

An Austrian pharmaceuticals company has reportedly prevailed in a €2 billion ICC dispute with a Taiwanese partner that sought to end their agreement to develop and market a blood cancer drug.


Get unlimited access to all Global Arbitration Review content